Vimarsana
Biggest News Aggregation in the World

Page 7 - Neuraxis Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neuraxis Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neuraxis Inc Today - Breaking & Trending Today

EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids - Neuraxis (AMEX:NRXS) - Vimarsana News

EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids - Neuraxis (AMEX:NRXS)

NeurAxis Inc (NYSE: NRXS) highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS), a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim in children with post-conc

Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids - Vimarsana News

Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids

NeurAxis Inc NRXS highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with…

Source: biztoc.com
Baystreet.ca - This Could Help Treat Post-Concussion Syndrome in Children - Vimarsana News

Baystreet.ca - This Could Help Treat Post-Concussion Syndrome in Children

Every year, an estimated 1.6 million to 3.8 million sports- and recreation-related concussions are seen, as noted by the Brain Injury Research Institute (BIRI), adding that, “During 2001-2005, children and youth ages 5-18 years accounted for 2.4 ...

NeurAxis (NASDAQ:NRXS) Research Coverage Started at Westpark Capital - Vimarsana News

NeurAxis (NASDAQ:NRXS) Research Coverage Started at Westpark Capital

Westpark Capital began coverage on shares of NeurAxis (NASDAQ:NRXS – Free Report) in a research report report published on Wednesday morning, FlyOnTheWall reports. The firm issued a buy rating on the stock. NeurAxis Stock Down 4.4 % NeurAxis stock opened at $5.16 on Wednesday. NeurAxis has a 12-month low of $4.45 and a 12-month high […]

NeurAxis Is Changing The Pediatric IBS And FAP Treatment Landscape To Drug-Free ($NRXS) - Vimarsana News

NeurAxis Is Changing The Pediatric IBS And FAP Treatment Landscape To Drug-Free ($NRXS)

NeurAxis is doing something other companies can't or won't do: provide a drug-free way to treat debilitating pediatric conditions, including Irritable Bowel Syndrome and Functional Abdominal Pain ....